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Summary Bryostatin 1 is a novel antitumour agent derived from Bugula neritina of the marine phylum
Ectoprocta. Nineteen patients with advanced solid tumours were entered into a phase I study to evaluate the
toxicity and biological effects ofbryostatin 1. Bryostatin 1 was given as a one hour intravenous infusion at the
beginning of each 2 week treatment cycle. A maximum of three treatment cycles were given. Doses were
escalated in steps from 5 to 65jigm-2 in successive patient groups. The maximum tolerated dose was
50figm2. Myalgia was the dose limiting toxicity and was of WHO grade 3 in all three patients treated at
65figm-2. Flu-like symptoms were common but were ofmaximum WHO grade 2. Hypotension, ofmaximum
WHO grade 1, occurred in six patients treated at doses up to and including 20jig m 2 and may not have been
attributable to treatment with bryostatin 1. Cellulitis and thrombophlebitis occurred at the bryostatin I
infusion site of patients treated at all dose levels up to 50jigm-2, attributable to the 60% ethanol diluent in
the bryostatin 1 infusion. Subsequent patients treated at 50 and 65jigm-2 received treatment with an
intravenous normal saline flush and they did not develop these complications. Significant decreases of the
platelet count and total leucocyte, neutrophil and lymphocyte counts were seen in the first 24 h after treatment
at the dose of 65 jig m2. Immediate decreases in haemoglobin of up to 1.9g dl-' were also noted in patients
treated with 65 iLgm2, in the absence of clinical evidence of bleeding or haemodynamic compromise. No
effect was observed on the incidence of haemopoietic progenitor cells in the marrow. Some patients'
neutrophils demonstrated enhanced superoxide radical formation in response to in vitro stimulation with
opsonised zymosan (a bacterial polysaccharide) but in the absence of this additional stimulus, no bryostatin 1
effect was observed. Lymphocyte natural killing activity was decreased 2 h after treatment with bryostatin 1,
but the effect was not consistently seen 24 h or 7 days later. With the dose schedule examined no antitumour
effects were observed. We recommend that bryostatin 1 is used at a dose of 35 to 50jg m-2 two weekly in
phase II studies in patients with malignancies including lymphoma, leukaemia, melanoma or hypernephroma,
for which pre-clinical investigations suggest antitumour activity.
Bryostatin 1 is a natural product isolated from the marine
invertebrate Bugula neritina, a member of the phylum Ecto-
procta (Pettit et al., 1982). The drug has a complex macro-
cyclic lactone stucture with a molecular weight of 904 daltons
(see Figure 1) and is the prototype of a novel family of
potent activators ofprotein kinase C (PKC: Berkow & Kraft,
1985; Fields et al., 1988). Bryostatin 1, in common with
phorbol esters which are also potent activators of PKC (Cas-
tagna et al., 1982), elicits a wide range ofbiological responses
including induction of differentiation, haemopoietic stimula-
tion, platelet aggregation and immunoenhancing activity.
However in a number of systems bryostatin 1 behaves
differently from the phorbol esters. Unlike phorbol esters,
bryostatin 1 does not induce differentiation of human bron-
chial epithelium (Jetten et al., 1989) or primary mouse
epidermal cells (Sako et al., 1987) and pre-treatment with
bryostatin 1 can serve to inhibit the phorbol ester response.
In addition, bryostatin 1 can cause protein phosphorylation
at doses that require a far greater molar concentration of
phorbol ester to achieve the effect (Fields et al., 1988; Warren
et al., 1988). Furthermore, unlike phorbol ester, bryostatin 1
is inactive as a complete tumour promoter or carcinogen and
acts to inhibit the tumour promoting properties of phorbol
esters (Hennings et al., 1987).
Bryostatin I has been shown to have significant in vitro
antineoplastic effects against murine and human leukaemia
cell lines, the L1OA B-cell lymphoma, the M5076 reticulum
cell sarcoma, ovarian carcinoma, the melanoma cell lines
SK-MEL5 and B16, the renal cell line A549 and the lung
carcinoma cell line A704 (NCI Antitumour Screening Pro-
gram; Pettit et al., 1982; Dale & Gescher, 1989; Kraft et al.,
1989; Hornung et al., 1992). In addition, significant
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antitumour activity has been observed in in vivo murine
models for leukaemia, ovarian carcinoma, B-cell lymphoma,
reticulum cell sarcoma and melanoma (Pettit et al., 1982;
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Figure 1 Bryostatin I structure.
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Schuchter et al., 1991; Hornung et al., 1992). Recently it has
been demonstrated in mice that there is a close correlation
between the in vitro and in vivo antitumour effect of bryo-
statin 1, suggesting a direct mechanism of action for the drug
in vivo (Hornung et al., 1992).
Numerous studies have demonstrated the potent
differentiating effect of bryostatin 1, particularly on fresh
human acute and chronic myelogenous and lymphocytic
leukaemias (Kraft et al., 1989; Lilly et al., 1990; Gignac et
al., 1990; Lilly et al., 1991). However, bryostatin 1 has shown
varying ability to differentiate immortal HL 60 chronic
myelomonocytic leukaemia cell lines, ranging from some
differentiation to little or no effect (Kiss et al., 1987a; Kiss et
al., 1987b; Kraft et al., 1989; Stone et al., 1988; William et
al., 1988; Warren et al., 1988). The terminal differentiating
effect of bryostatin 1 would appear to produce cytostasis in
immortal human cell lines (Jones et al., 1990) but is largely
cytotoxic in a variety of fresh human myeloid leukaemia cells
(Lilly et al., 1990; Lilly et al., 1991). Here it has been
suggested that the differential effect of bryostatin 1 on fresh
and immortal leukaemia cells may exist because of
differential expression of PKC isoenzymes (Lilly et al., 1991).
Bryostatin 1 also induces terminal differentiation of other
cells, including conversion of immortal high grade Burkitt
lymphoma cells to cells with surface polypeptides characteris-
tic of intermediate grade cells (Al-Katib et al., 1990) and
transient transformation of immortal human neuroblastoma
cells to mature ganglion cells (Jalava et al., 1990).
As a consequence of the potent antineoplastic and
differentiating effects of this novel agent, we have undertaken
a phase I study of intravenous bryostatin 1 in patients with
advanced cancer.
Materials and methods
Drug supply andformulation
The bryostatin 1 used in this phase I trial was extracted from
Bugula neritina. The extraction was undertaken at the NCI-
Frederick Cancer Research Facility, Frederick, MD 21701,
USA. Formulation and stability studies were carried out by
Dr John Slack at the CRC Experimental Cancer Chemo-
therapy Research Group, Pharmaceutical Sciences Institute,
Aston University, Aston Triangle, Birmingham, B4 7ET,
UK.
Physicalproperties
Bryostatin 1 is a colourless, odourless, crystalline substance,
relatively insoluble in water and normal saline, but very
soluble in 100% ethanol (greater than 4000 igml-'). The
solubility of bryostatin 1 in a solution of 60% ethanol and
40% normal saline is 97figml1'. Bryostatin 1 is formulated
in 1.5 ml of a 0.1 mg mlV
' solution in 100% ethanol BP in
clear glass ampoules (i.e. 0.15 mg per ampoule). A 0.1 mg
ml-' solution in absolute ethanol BP shows no sign of
degradation after 3 weeks at 500 or 20°C in daylight or after
eight months at -20°C. Bryostatin 1 is stable for 24 h in a
60% ethanol solution in 0.9% normal saline in a poly-
propylene syringe.
Preclinical toxicology
Precinical toxicology on bryostatin 1 was carried out in both
mice and rats by BIBRA, Carshalton, Surrey, UK and spon-
sored by the Cancer Research Campaign (CRC) UK.
Analysis of the murine mortality data using computer linear
regression techniques gave an LD,o value of 0.029 mg kg-'
(95% confidence limits of 0.022-0.037 mg kg-') and an LD50
value of 0.038 mg kg-' (95% confidence limits of 0.033-
0.042 mg kg-'). Analysis of the rat mortality data by similar
techniques gave an LDIo value of 0.045 mgkg-' and an LD50
value of 0.068 mg kg-'. Following treatment with bryostatin
1 most of the animals showed initial signs of lethargy, uns-
teady movement and in some cases haematuria. The majority
ofdeaths occurred within one day ofdosing with animals not
recovering from the lethargy and unsteady movement seen at
the time of dosing. Animals showed a slight decrease in
bodyweight at the beginning of the observation period but
recovered to control weights by the end of the study. The
main effects on organ weights were an increase in liver weight
on day 15 and an increase in spleen weight relative to
bodyweight on day 29. The haematological data in rats
showed the platelet numbers to be significantly reduced on
day three of the study with a return to normal levels on day
seven. The number of circulatory lymphocytes was also
significantly reduced on day three and remained significantly
lower in most of the animals throughout the 29 day study
period. Rats which died soon after treatment were found to
have haemorrhage in the lung, muscle and thymus and
perivascular oedema and intravascular fibrous deposition in
the lung. Mice were not subjected to haematological inves-
tigation and mice dying soon after bryostatin 1 dosing were
not subjected to gross necropsy examination. Most animals
were found to have significant tail vein necrosis which may
have been solely due to the ethanol diluent used in the
administration of bryostatin 1.
Study design
Bryostatin 1 was administered as an intravenous infusion of
2 ml of 60% ethanol BP in 40% normal saline over one
hour. Patients received a single infusion on day one of each
two week treatment cycle. A maximum of three treatment
cycles (i.e. three bryostatin 1 infusions) was given. One tenth
of the murine LDIo value was 5 ytg m-2 and this was chosen
as the starting dose. The study design was for three patients
to be entered at each of the following dose levels: 5, 10, 20,
35, 50 and 65 jig m2. There was no dose escalation within
the same patient. The study endpoint was a maximum
tolerated dose (MTD) resulting in a severe or life threatening
toxicity (WHO grade 3 or 4) in any system in 66% of
patients.
Patients
Nineteen patients were entered into this study. All had
advanced solid tumours for which conventional therapy was
not available or had failed (see Table I). Inclusion criteria
were a Karnofsky performance status of >,70, age greater
than 18 years, life expectancy of at least three months and a
negative stool guaic. The patients had to have normal
coagulation (prothrombin time and partial thromboplastin
Table I Patient characteristics
Bryo Dose Completion of
Pt. No. Diagnosis jAgm-2 treatment
1 Ovar Ca. 5 Yes
2 Ovar Ca. 5 Yes
3 Ovar Ca. 5 Yes
4 Ovar Ca. 10 Yes
5 Mesothelioma 10 No (Disease progression)
6 Mesothelioma 10 Yes
7 Mesothelioma 20 Yes
8 Mesothelioma 20 Yes
9 Mesothelioma 20 Yes
10 Ovar Ca. 35 Yes
11 Mesothelioma 35 Yes
12 Ovar Ca. 50 Yes
13 Ovar Ca. 50 No (Disease progression)
14 Ovar Ca. 50 Yes
15 Sarcoma 50 Yes
16 Sarcoma 50 No (Disease progression)
17 Colon Ca. 65 Yes
18 Ovar Ca. 65 No (Toxicity)
19 Ovar Ca. 65 No (Toxicity)
Pt. No = patient trial number; bryo = bryostatin 1; ovar
ca = ovarian carcinoma. Reasons for not completing treatment
indicated in parenthesis.420 J. PRENDIVILLE et al.
time,( 1.2 times the laboratory controls), normal renal func-
tion (serum creatinine <0.12 mmol 1') and adequate hepatic
function (bilirubin <25 ymol1l-I and serum liver transa-
minases <2.0 times normal). Patients were advised not to
consume aspirin because of the risk of haemorrhagic gas-
tritis. Patients were excluded from the study if they had
received any other antitumour treatment within 3 weeks of
study entry, had major surgery within four weeks of study
entry, had brain metastases or a known seizure disorder, or
were fertile men and women not using an acceptable method
of contraception, seropositive for HIV or had other serious
intercurrent illness. Any patient with a history of peptic
ulceration or gastrointestinal bleeding or a history of any
bleeding disorder was also excluded.
Clinical and laboratory monitoring
Regular haematological and biochemical investigations were
performed before and during treatment with bryostatin 1.
These included full blood counts, white cell differentials,
measurement of prothrombin and partial thromboplastin
times, full biochemistry screen (including liver function tests)
and urinalysis. Because of the risk of platelet aggregation,
additional full blood counts were performed at 1A, 1, 2 and
4 h after each bryostatin 1 infusion. The clinical state of the
patients was monitored by physical examinations, recordings
of weight, blood pressure, radial pulse and oral temperature.
Creatinine phosphokinase levels and electromyography were
performed in patients treated at the highest dose level
(65 isg m-2).
Clonogenic assays
Bone marrow aspirates were taken under local anaesthetic
from the posterior superior iliac crest for in vitro clonogenic
assays before treatment and 24 h after the final bryostatin 1
infusion. Twenty ml of heparinised venous blood were col-
lected on the same days. Bone marrow cells for in vitro
manipulation were collected in Iscove's medium (Gibco) with
50 units of preservative free heparin (CP Pharmaceuticals
Ltd). Three aliquots of this suspension were prepared and
clonal assays performed as described previously (Testa, 1985)
with minor modifications. Briefly, red cells were removed by
sedimentation in 0.1% methylcellulose over 30 min at room
temperature. The stromal cell population (CFU-F, Colony
forming unit-fibroblast) was assayed by suspending cells at
1 x I05 ml1 in 5 ml of 15% horse serum (Medical Veterinary
Supplies) in Iscove's medium in flasks (Falcon T25) gassed
with 5% CO2 and incubating for 10 days at 37'C. The flasks
were washed with phosphate buffered saline and the adherent
cells fixed in methanol and stained with Crystal Violet. Col-
onies containing more than 50 fibroblasts were scored. The
Ficoll (Flow) separated mononuclear fraction of the second
aliquot of bone marrow cells was plated at 105 cells ml-' in
1.2% methycellulose, 10% conditioned medium from the
5637 bladder carcinoma cell line (as a source of colony
stimulating factors), two units of recombinant erythropoietin
(Terry Fox Lab), 1% bovine serum albumin (Sigma) and
30% foetal calf serum (Flow Laboratories) in Iscove's
medium. Colonies of more than 50 cells were scored using
standard criteria as BFU-E (Burst forming unit-erythroid),
GM-CFC (Granulocyte macrophage-colony forming cells)
and Mix-CFC (Mixed lineage - colony forming cells) after 14
days of incubation at 37C in a humidified incubator gassed
with 5% CO2 and 5% 02 in nitrogen.
NK assays
Venous blood taken pre-treatment and 2 h, 24 h and 7 days
following treatment was used to assess the immunological
responses to byrostatin 1. Peripheral blood mononuclear cells
(PBMC) were isolated from 40 ml of heparinised blood by
lymphocyte separation medium (Flow Laboratories).
Fresh PBMC were effectors in a 4 h 5"Cr release assay to
assess the level of NK and endogenous LAK activity against
K562, an erythroleukaemia cell line (NK sensitive and LAK
sensitive) and Daudi, a Burkitt's lymphoma cell line (NK
resistant and LAK sensitive). PBMC were assayed in trip-
licate at effector to target cell ratios of between 40:1 and
10:1 with 5 x 103 5'Cr labelled target cells per well. These
were then incubated at 37°C with 5% CO2 overlay for 4 h.
Cytotoxicity was calculated according to the formula:
% cytotoxicity =
51Cr release test - spontaneous 51Cr release
maximum "Cr release - spontaneous 51Cr release
Spontaneous release was obtained by incubating target cells
with medium only and maximum release by incubation of
target cells with 2% (v/v) Tween 20 (Sigma) in PBS. A more
detailed description of this method is given by Ghosh et al.
(1989).
Polymorphfunction tests
Cells Leucocyte populations from peripheral blood were
prepared by dextran sedimentation of heparinised blood and
residual red cells removed by H20 Iysis. Cells were washed
twice in Hanks balanced salt solution (Flow Labs), re-
suspended in HEPES buffered RPMI-H medium (RPMI
1640, Flow Labs) and counted on a haemocytometer.
Polymorph phagocytic function Phagocyte function was
measured essentially as described by Easmon et al. (1980) by
the technique of luminol-dependent chemiluminescence using
zymosan as the stimulating agent. The test was performed
using disposable polystyrene cuvettes (Clinicon) containing
700jtl luminol (Sigma 10-4 M in RPMI-H), 200 LI of freshly
opsonised zymosan (Zymosan A, Sigma) and 100yil cell
suspension (containing 5 x 106 polymorphs ml-'). Cuvettes
were counted repeatedly at 3 min intervals for 30 min using a
LKB 1251 Luminometer and the results expressed as mean
values for the peak chemiluminescence (in mV). All samples
were set up in duplicate.
Results
Nineteen patients were entered into this study, three at each
of the dose levels 5, 10 and 20,.gm-2, two at 35 1tg m-2, five
at 50ttgm2 and three at 65gLgm2 (see Table I). Twelve
patients had received prior intensive chemotherapy. Six
patients with mesothelioma and one patient with colon
cancer had received no prior chemotherapy or radiotherapy.
Toxicity
The severity and duration of clinical toxicity was dose
related. Several patients developed increasing severity of
symptoms with repeated injections of bryostatin 1. Flu-like
symptoms of maximum WHO grade 2, (ie moderate
severity), such as lethargy, fever, sweats, rigors, rhinitis and
headache accounted for most of the clinical toxicity (see
Table II). Hypotension, of maximum WHO grade 1, occur-
red in six patients. The dose limiting toxicity was myalgia,
often associated with mild to moderate muscle tenderness.
Several patients complained of retro-orbital pain on moving
their eyes, and upper dysphagia, both of which we attributed
to myalgia in these areas. One patient developed WHO grade
2 myalgia at the starting dose level of 5 pgm-2. Other
patients treated at 5 lgm2 and patients treated at 10 and
20 sgm-2 did not develop this side effect. Both patients
treated at the dose level of 35 tg m-2 and three of the
patients at 50 yg m-2 developed myalgia which was of max-
imum WHO grade 2. All three patients treated at 65jigm-2
developed WHO grade 3 myalgia which necessitated
confinement to bed for one or more days, or which required
significant amounts of analgesia to relieve the discomfort.
One of these three patients developed WHO grade 3 myalgia
following the first cycle of treatment and the other twoBRYOSTATIN 1 IN ADVANCED CANCER PATIENTS 421
Table II Clinical toxicity
5 tLgm-2 day-] 10 Lg m-2day-' 20 lg m-2day-/
9 cycles (3 pts) 7 cycles (3 pts) 9 cycles (3 pts)
No. cycles/max. WHO No cycles/max. WHO No. cycles/max. WHO
1 2 3 4 1 2 3 4 1 2 3 4
Lethargy 1 2 4 1
Fever 3 2 1 2
Hypotension 3 4
Sweats 2
Rigors
Rhinitis
Headache
Myalgia I
Retro-orbital
pain
Dysphagia
35 ILgm-2 day ' 50 llg m-2 day ' 65ilg m-2day'
6 cycles (2 pts) 12 cycles (5 pts) 6 cycles (3 pts)
No. cycles/max. WHO No cycles/max. WHO No. cycles/max. WHO
1 2 3 4 1 2 3 4 1 2 3 4
Lethargy 5 1 2 4
Fever 3 4 3
Hypotension 1
Sweats 1 1 1
Rigors 1 1 1
Rhinitis 2
Headache 2 2 3
Myalgia 4 1 6 3 3
Retro-orbital 2 2
pain
Dysphagia I
No. cycles/max. WHO = the maximum toxicity attained during a cycle of treatment and
the number of cycles in which this occurred.
patients following the second and third cycles of treatment
respectively. They were not given subsequent cycles of treat-
ment. Several patients complained of myalgia getting worse
with successive cycles of treatment but this was not true of
all patients. The pathogenesis of the myalgia is unknown.
Creatinine phosphokinase levels remained within the normal
range in the three patients who developed WHO grade 3
myalgia. Electromyography was performed also in all three
patients and was normal in two. The third patient's electro-
myographic trace was slightly abnormal and showed several
areas of muscle where there were short polyphasic units and
which could be compatable with some patchy myositis.
Cellulitis and thrombophlebitis at the bryostatin 1 infusion
site complicated 19 of the total 36 cycles of treatment given
to the patients treated up to 35jg m-2 and two of the
patients treated at 50 lg m-2. These complications occurred
at all dose levels but slightly more regularly at the higher
dose levels. We believe that the ethanol diluent was the major
cause of the phlebitis and cellulitis when it occurred but we
cannot exclude bryostatin 1 itself as a contributory factor.
Subsequent patients treated at 50 and 65 ,tg m-2 received an
intravenous normal saline infusion with their bryostatin 1
treatment in order to flush the bryostatin 1 solute and
ethanol diluent from the treatment vein. There was only one
case of mild phlebitis out of a total 13 cycles of treatment
given in this way.
There were no apparent effects on coagulation, serum
biochemistry or liver function assessed regularly following
treatment with bryostatin 1.
Effects ofbryostatin I on blood count
There were no significant changes in any of the haematologic
parameters during the administration ofbryostatin 1 at doses
of 5, 10, 20, 35 and 50 igm2 day-'. The three patients
treated at the dose of 65 .tg m-2 showed decreases of
34-44% in platelet counts with the nadir occurring in the
first 4 h. Recovery of the platelet count was usually taking
place at 24h following treatment and full recovery was
usually evident at one week (Figure 2).
A reduction in the neutrophil count also occurred in the
first 24 h following administration with decreases of 44-64%
at 65 jtg m-2 (Figure 3). Reductions in the lymphocyte count
also occurred with decreases of 55-88% at 65 ytgm-2
(Figure 3).
Of particular interest were immediate decreases in haemo-
globin values observed in the first 4 h after treatment with
bryostatin 1, most notable in patients treated at the dose of
65 Lgm-2 with decreases of up to 1.9 gdl-' (see Figure 4).
Unlike decreases in platelet, neutrophil and lymphocyte
counts, recovery of the haemoglobin values was not noted in
the next 2 weeks. There was no clinical evidence of bleeding
and the patients showed no evidence of haemodynamic com-
promise.
Bone marrow clonogenic assays
In vitro clonogenic assays of haemopoietic progenitors were
performed on bone marrow aspirates taken before the first
bryostatin 1 infusion and 24 h after the final treatment from
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Figure 2 Platelet counts measured over the first 24 h and then at
one week following administration of the first cycle of bryostatin
1 in the three patients treated at the dose of 65 gm-2.422 J. PRENDIVILLE et al.
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Figure 3 Neutrophil ( ) and lymphocyte (------) counts
measured over the first 24h and then at one week following
administration of the first cycle of bryostatin 1 to the three
patients treated at the dose of 65Agm-m2.
Table HI Percentage increase from baseline value of maximum
neutrophil superoxide radical formation (as detected by
chemiluminescence) following in vitro stimulation with opsonised
zymosan
Percentage charge over pre treatment level
Byro 2 hours post 24 hours post
Pt No tgm-2 treatment treatment
7 20 + 29 + 46
8 20 N.C. N.C.
10 35 N.C. N.C.
11 35 +26 +33.2
12 50 + 181 + 113
13 50 N.C. N.C.
14 50 N.C. N.C.
15 50 N.C. + 59
16 50 + 30 + 45.2
17 65 N.C. N.C.
18 65 N.C. + 33.4
19 65 N.C. + 40.2
Pt No =patient trial number, bryo I = bryostatin 1; N.C. = no
change from pre treatment result and includes increases or decreases
of up to 25%.
Discussion
0 1/2 1 2
Hours
4 24 168
Figure 4 Haemoglobin measurements over the first 24 h and
then at one week following administration of the first cycle of
bryostatin I to the three patients treated at the dose of
65 sgm-2.
one patient treated at the dose of 50 jig m-2 and two patients
treated at 65 igm-2. No in vivo effect of bryostatin 1 on
haemopoietic progenitor cells was demonstrated (data not
shown).
NK activity
In patients 14 to 18, a decrease in the NK activity (against
K562) was observed 2 h following treatment (see Table IV).
In all cases, subsequent levels of NK were low but gradually
increased over the 7 day observation period. Endogenous
LAK activity (against Daudi cells) followed a similar trend.
No dose-dependent differences were observed in NK activity.
Neutrophil chemiluminescence
Maximum neutrophil superoxide radical formation detected
by chemiluminescence was measured pre treatment and at 2 h
and 24 h following a single bryostatin 1 infusion in patients
treated at 20, 35 50 and 65 fig m2. No significant effect of
bryostatin 1 was observed on neutrophils in the absence of
opsonised zymosan (a bacterial polysaccharide). If neutro-
phils were additionally stimulated, with opsonised zymosan
significant increases in the maximum neutrophil chemilum-
inescence recorded were observed in some patients (see Table
III). Increases or decreases of greater than 25% are thought
to be within the error range of the assay and are not shown.
Bryostatin 1 is a potent activator of PKC which elicits a wide
range of biological effects, including platelet aggregation,
enhancement of the production and function of haemopoietic
growth factors, activation of intact polymorphonuclear
leucocytes, pleiotropic immunoenhancing effects on both T
and B lymphocytes, induction of differentiation and potent in
vitro and murine in vivo antineoplastic effects. In vitro studies
have shown bryostatin 1 to be extremely active in the
nanomolar range. Preclinical toxicology on bryostatin 1
confirmed similar in vivo potency with a murine LDIo value
of 0.029 mg kg-'. Bryostatin 1 therefore entered phase 1
clinical trial at a dose of 5 gm2.
Flu-like symptoms such as lethargy, fever, sweats, rigors,
rhinitis and headache accounted for the majority of clinical
toxicity but they were of maximum WHO grade 2. Mild
hypotension occurred in six patients treated at doses up to
and including 20iLg m-2 and may not have been attributable
to treatment with bryostatin 1. Myalgia, aggravated by exer-
cise, emerged as the dose limiting toxicity usually occurring
about 48 h after threatment and lasting up to several weeks
at the highest dose levels. Several patients complained of
increasing myalgia with successive cycles of treatment. The
pathogenesis of this toxicity is uncertain and there was no
clear evidence compatible with either myositis or myolysis.
Muscle tenderness was evident in many patients but was not
a prominent feature. Electromyography (EMG) demonstrat-
ed some evidence of patchy myositis in one of three patients
treated at 65 Ltgm-2. Serum creatinine phosphokinase (CPK)
levels remained within the normal range in the same three
patients. In vitro work has shown that bryostatin 1, like other
protein kinase C activators, induces electrical membrane in-
stability in genetically normal muscle, leading to an unsche-
duled series of action potentials (Brinkmeier & Jockusch,
1987). These findings were caused by a drastically lowered
sarcolemma chloride conductance. If this was the cause of
the myalgia in our patients, one would have expected florid
changes on the EMG's which did not occur. Another possi-
ble explanation for the myalgia is ischaemia cause by platelet
microemboli (i.e. platelet aggregates) but there was no rise in
CPK levels secondary to ischaemia-induced necrosis.
Cellulitis and thrombophlebitis at the bryostatin 1 infusion
site complicated 53% of cycles of treatment administered
without an accompanying normal saline venous flush. We
believe that these complications resulted from the 60%
ethanol diluent in the bryostatin 1 infusion, though we can-
not exclude the possibility that the bryostatin 1 itself may
have been a contributing factor.
Bryostatin 7 has been shown to be a potent inducer of
human platelet aggregation in vitro (Tallant et al., 1987) and
we have demonstrated similar activity by bryostatin 1 in vitro
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Table IV Lymphocyte natural killing activity as measured by % cytotoxicity of either K562 or Daudi
cells
Percentage cytotoxicity
Pt Byro 1 Pre treatment 2 hours 24 hours 7 days
No 1ig m-2 K562 Daudi K562 Daudi K562 Daudi K562 Daudi
14 50 4.1 2.2 0.8 4.0 12.7 1.7 5.4 1.6
15 50 4.8 3.0 0.0 0.0 4.2 0.1 3.0 13.3
16 50 6.3 21.5 1.2 2.3 13.4 12.3 16.1 10.7
17 65 21.5 35.7 7.0 5.7 11.8 5.2 7.5 5.2
18 65 20.3 5.8 2.5 0.0 11.8 0.11 16.1 5.3
19 65 6.0 10.0 ND ND 7.4 2.2 16.4 7.6
Pt No = patient trial number; bryo I = broystatin 1; ND = no data.
and in vivo (data not shown). Mouse and rat toxicity studies
have also shown a profound in vivo effect of bryostatin 1 on
platelets. In this phase 1 study we observed a drop in platelet
counts only at the bryostatin 1 dose of 65 jig m-2, occurring
usually up to 4 h after treatment. Platelet aggregation was
not profound and decreases of only 34-44% in the platelet
count were observed. Pre-clinical toxicity studies demon-
strated more profound platelet count drops and occasionally
with significant internal bleeding, but at relatively higher
bryostatin 1 doses than we used in this phase 1 trial. The
emergence of dose limiting myalgia has meant that we did
not approach bryostatin 1 doses in this trial where we might
encounter profound platelet aggregation and run a significant
risk of bleeding.
Decreases in the haemoglobin values of up to 1.9 gdl- in
patients treated at the bryostatin 1 dose of 65 lg m-2 are
unexplained. There was no clinical evidence of bleeding or
haemodynamic compromise. Haemolysis may explain the
finding.
Transient reductions in the neutrophil and lymphocyte
counts also occurred at the dose of 65jLg m-2 in the first 24 h
after treatment. These may have been due to the sequestra-
tion of functionally active leucocytes. No evidence of toxicity
on haemopoietic progenitor cells was found in clonogenic
studies on bone marrow taken from these patients. Pre-
clinical toxicity studies have demonstrated significant reduc-
tions in lymphocyte counts lasting up to 29 days after treat-
ment with bryostatin 1, but at relatively higher doses than we
achieved in this phase 1 trial.
Bryostatin 1 functionally activates intact human polymor-
phonuclear leucocytes, enhancing cytotoxicity and release of
superoxide radicals and specific granules (May et al., 1987;
Berkow & Kraft, 1985). We were unable in this phase I trial
to clearly demonstrate enhanced production of superoxide
radicals by neutrophils taken from patients treated with
bryostatin 1 at doses of 20, 35, 50 and 65jlgm-2. However,
if these neutrophils were additionally stimulated in vitro,
using opsonised zymosan an enhanced production of
superoxide radicals were seen in seven patients at doses of 20,
35, 50 and 65 jig m-2. The doses of bryostatin 1 administered
in this phase 1 trial were not on their own, enough to
stimulate directly the release of superoxide radicals but were
sufficient to 'prime' the neutrophils for an enhanced response
to a second stimulus.
Bryostatin 1 exerts pleiotropic effects on human lym-
phocytes in vitro including the activation and induction of
proliferation of both T and B cells (Trenn et al., 1988; Hess
et al., 1988; Drexler et al., 1990) and the induction of
interleukin-2 receptors (IL-2R) on T cells (Hess et al., 1988).
Conflicting evidence exists on the ability of bryostatin 1 to
enhance or trigger human lymphocyte mediated cytotoxicity.
Trenn et al., 1988, have reported on the ability of bryostatin
1 to trigger cytotoxic T lymphocyte (CTL) development in
naive resting lymph node cells and to trigger cytotoxicity of
CTL clones against antigen (Ag) - non bearing target cells.
However, CTL cytotoxicity against Ag-specific target cells
was inhibited. Bryostatin 1 was also shown to greatly
enhance the efficiency of recombinant interleukin-2 (rIL-2) in
triggering development of in vivo primed CTL during in vitro
incubation. In all patients monitored in our study the NK
activity decreased initially following administration of bryos-
tatin 1. However, since the actual values obtained for %
cytotoxicity were low the significance of these differences has
to be interpreted with caution. Similar observations were
made in vitro by Tilden and Kraft (1991) who found a
suppression of NK activity following an 18 h preincubation
of lymphocytes with 10-8 M bryostatin 1. These authors also
observed reduced cytotoxic activity of LAK effector cells
following coincubation with rIL-2 and 10-8 M bryostatin 1. It
will be of interest to study the in vitro LAK activities of
lymphocyte populations of patients receiving bryostatin 1.
Bryostatin 1 exerts a wide variety of stimulatory effects on
bone marrow progenitor cells and peripheral blood cells.
Originally bryostatin 1 was reported to enhance proliferation
of human and murine haemopoietic progenitor cells, includ-
ing committed myeloid progenitor cells (CFU-GM) and early
and late erythroid progenitors (BFU-E and CFU-E: May et
al., 1987; Leonard et al., 1988; Gebbia et al., 1988). Subse-
quently it has been shown that this is an indirect effect and
includes the augmentation of the response by haemopoietic
progenitors to the haemopoietic growth factors, granulocyte
macrophage colony stimulation factor (GM-CSF) and
interleukin-3 (IL-3: McCrady et al., 1991; Sharkis et al.,
1990) and perhaps also the stimulation of accessory cell
populations, including T cells, to produce GM-CSF and IL-3
(Sharkis et al., 1990; Leonard et al., 1988). We were unable
in this phase 1 trial to demonstrate changes in the incidence
of progenitor cells in the marrow.
Pre-clinical studies have demonstrated that bryostatin 1 is
an extremely potent antineoplastic agent. The marine animal
origin, macrocylcic lactone structure and PKC receptor
mechanism make it one of the most unusual anti-tumour
agents to become available for phase I clinical testing. In
addition, only extremely low doses are required to produce a
biological effect in vivo. We recommend phase II clinical
testing at a bryostatin 1 dose of 35 to 50jigm-2 two weekly
in patients with malignancies including lymphoma, leuk-
aemia, melanoma or hypernephroma for which preclinical
studies suggest antitumour activity. We are currently
evaluating weekly treatments by 24 h infusion at a bryostatin
1 dose of 25 to 50 tLg m in patients with malignancies
including lymphoma.
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